Cooper Joseph Patrick 4

What Happened
Joseph Patrick Cooper, a director of Quoin Pharmaceuticals, was granted a derivative award of 8,141 American Depositary Shares (ADSs) on February 4, 2026. The award was reported at $0.00 (no cash paid) and is recorded as a grant/award (transaction code A). Each ADS represents 35 ordinary shares, so the award corresponds to 284,935 underlying ordinary shares.

Key Details

• Transaction date: February 4, 2026; Form 4 filed February 6, 2026 (timely filing).
• Award size: 8,141 ADSs at $0.00 (derivative award). Equivalent ordinary shares: 8,141 × 35 = 284,935.
• Vesting (footnote): Vests in four annual installments — 20% on Feb 4 of 2027, 2028 and 2029, and 40% on Feb 4, 2030.
• Shares owned after transaction: Not specified in the provided filing details.
• Notes: The filing lists the grant in ADS terms (each ADS = 35 ordinary shares) and classifies the item as a derivative award. No sale or immediate disposition of shares was reported.

Context
This is a compensation-related award to a director, not an open-market purchase or sale. The award is subject to multi-year vesting, so the director does not receive full, unrestricted ownership immediately. Such grants are commonly used for director compensation and do not by themselves indicate buy/sell intent.